Double immunotherapy plus liver blockade targets eye cancer that spreads
NCT ID NCT03472586
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This trial investigates whether combining two immunotherapy drugs (ipilimumab and nivolumab) with a procedure called immunoembolization can help people whose uveal melanoma has spread to the liver. The drugs help the immune system attack cancer cells, while immunoembolization cuts off the blood supply to liver tumors and may also trigger an immune response. The study includes people with at least one measurable liver metastasis and aims to see if this combination can stabilize or shrink liver tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ipilimumab and nivolumab (immunotherapy drugs) plus immunoembolization (a procedure that blocks blood flow to liver tumors)
- What this could lead to
- If it works, this combination could offer a new way to control liver metastases from uveal melanoma, potentially slowing or stopping tumor growth.
- What could go wrong
- This is a small, early-phase trial with only 14 participants. The added drugs and procedure may cause serious side effects, and the approach may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE LIVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink Hard-to-Treat eye cancer?
- First-in-Class cancer drug targets Hard-to-Treat tumors
- Can a vaccine keep melanoma from coming back? large trial tests immune boosters
- Engineered immune cells take on Hard-to-Treat melanoma
- Immune cell therapy shows promise against rare eye cancer
- Could a pill help the liver regrow and make more cancer surgeries possible?